Skip to menu Skip to content Skip to footer
Dr Cui Tu
Dr

Cui Tu

Email: 

Overview

Availability

Dr Cui Tu is:
Available for supervision

Qualifications

  • Doctor of Philosophy, The University of Queensland

Works

Search Professor Cui Tu’s works on UQ eSpace

9 works between 2022 and 2026

1 - 9 of 9 works

2026

Journal Article

Spatial multi-omics characterization of neuroblastoma reveals ferroptosis-associated metabolic features in high-risk tumors

Tu, Cui, Tan, Chin Wee, Monkman, James, Almeida, Ana Clara, Antonio-Carreon, Gabrielle, Omer, Natacha, Hull, Giaan, Chung, Kimberly, Mehdi, Ahmed M., Salerno, Antonietta, Vittorio, Orazio, Mayer, Aaron, Machado-Souza, Cleber, Jayabalan, Nanthini, Toh, Yi-Chin, Hon, Hui Nee, de Almeida Brehm Pinhatti, Fernanda, Elifio-Esposito, Selene, Nicholls, Wayne, de Noronha, Lucia, Kulasinghe, Arutha and Souza-Fonseca-Guimaraes, Fernando (2026). Spatial multi-omics characterization of neuroblastoma reveals ferroptosis-associated metabolic features in high-risk tumors. Genome Medicine, 18 (1) 35. doi: 10.1186/s13073-026-01622-0

Spatial multi-omics characterization of neuroblastoma reveals ferroptosis-associated metabolic features in high-risk tumors

2026

Journal Article

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

Wong, Joshua K. M., Lam, Pui Yeng, Coleborn, Elaina, Alim, Louisa, Jose, Jiya, Tu, Cui, Antczak, Magdalena, Dietmair, Bettina, Hagh, Arghavan Golbaz, Noronha, Lucia, Cheetham, Seth W., Hooper, John, Beavis, Paul A., Merino, Delphine, Berthelet, Jean, Aoude, Lauren G., McCart-Reed, Amy E., Lakhani, Sunil, Simpson, Peter T., Rossi, Gustavo R., Brooks, Andrew J., Jones, Martina L., Simpson, Fiona and Souza-Fonseca-Guimaraes, Fernando (2026). Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. Molecular Therapy, 34 (3), 1382-1398. doi: 10.1016/j.ymthe.2025.11.021

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

2025

Conference Publication

Spatial profiling of tumor microenvironment uncovers potential novel therapeutic approach in pediatric neuroblastoma

Tu, Cui, Tan, Chin Wee, Monkman, James, Almeida, Ana Clara, Antonio-Carreon, Gabrielle, Omer, Natacha, Hull, Giaan, Chung, Kimberly, Mehdi, Ahmed, Salerno, Antonietta, Vittorio, Orazio, Mayer, Aaron, Machado de Souza, Cleber, de Almeida Brehm Pinhati, Fernanda, Elifio-Esposito, Selene, Nicholls, Wayne, de Noronha, Lucia, Kulasinghe, Arutha and Souza-Fonseca-Guimaraes, Fernando (2025). Spatial profiling of tumor microenvironment uncovers potential novel therapeutic approach in pediatric neuroblastoma. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-2705

Spatial profiling of tumor microenvironment uncovers potential novel therapeutic approach in pediatric neuroblastoma

2025

Journal Article

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

Lam, Pui Yeng, Omer, Natacha, Wong, Josh K. M., Tu, Cui, Alim, Louisa, Rossi, Gustavo R., Victorova, Maria, Tompkins, Hannah, Lin, Cheng-Yu, Mehdi, Ahmed M., Choo, Amos, Elliott, Melissa R., Coleborn, Elaina, Sun, Jane, Mercer, Timothy, Vittorio, Orazio, Dobson, Lachlan J., Mclellan, Alexander D., Brooks, Andrew, Tuong, Zewen Kelvin, Cheetham, Seth W., Nicholls, Wayne and Souza-Fonseca-Guimaraes, Fernando (2025). Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. Clinical and Translational Medicine, 15 (1) e70140, 1-21. doi: 10.1002/ctm2.70140

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

2024

Conference Publication

Natural Killer cell-based cancer immunotherapy for rhabdomyosarcoma

Rossi, Gustavo Rodrigues, Lam, Pui Yeng, Omer, Natacha, Tu, Cui and Souza-Fonseca-Guimaraes, Fernando (2024). Natural Killer cell-based cancer immunotherapy for rhabdomyosarcoma. Annual Meeting of the American Association of Immunologists (IMMUNOLOGY), Chicago, IL, United States, 3-7 May 2024. Cary, NC, United States: Oxford University Press. doi: 10.4049/jimmunol.212.supp.1399.5214

Natural Killer cell-based cancer immunotherapy for rhabdomyosarcoma

2024

Conference Publication

Spatial profiling of pediatric rhabdomyosarcoma to elucidate their immunosuppressive tumor microenvironment

Tu, Cui, Tan, Chin Wee, Liu, Ning, Kulasinghe, Arutha and Souza-Fonseca-Guimaraes, Fernando (2024). Spatial profiling of pediatric rhabdomyosarcoma to elucidate their immunosuppressive tumor microenvironment. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-73

Spatial profiling of pediatric rhabdomyosarcoma to elucidate their immunosuppressive tumor microenvironment

2024

Journal Article

Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis

Tu, Cui, Buckle, Irina, Leal Rojas, Ingrid, Rodrigues Rossi, Gustavo, Sester, David P., Moore, Andrew S., Radford, Kristen, Guillerey, Camille and Souza‐Fonseca‐Guimaraes, Fernando (2024). Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis. Clinical and Translational Immunology, 13 (3) e1501, 1-15. doi: 10.1002/cti2.1501

Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis

2024

Journal Article

Leveraging spatial omics for the development of precision sarcoma treatments

Tu, Cui, Kulasinghe, Arutha, Barbour, Andrew and Souza-Fonseca-Guimaraes, Fernando (2024). Leveraging spatial omics for the development of precision sarcoma treatments. Trends in Pharmacological Sciences, 45 (2), 134-144. doi: 10.1016/j.tips.2023.12.006

Leveraging spatial omics for the development of precision sarcoma treatments

2022

Journal Article

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA

Casey, Mika, Tu, Cui, Harrison, Simon J. and Nakamura, Kyohei (2022). Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. Blood Advances, 6 (17), 5165-5170. doi: 10.1182/bloodadvances.2022008118

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA

Funding

Current funding

  • 2026 - 2029
    Pioneering New Hope: Advancing Effective Treatments for Adolescent and Young Adult Sarcoma
    Research Donation Generic
    Open grant
  • 2025 - 2027
    Advancing insights into the immune landscape of pediatric ARDS lungs: A spatial multi-omics approach
    UQ - Sanofi Translational Science Hub Partnership Scheme
    Open grant
  • 2025 - 2026
    First-in-field combinatorial therapy using anti-tumoral STING agonist to enhance chemotherapy effectiveness for hard-to-cure rhabdomyosarcomas
    ANZ Sarcoma Research Grant
    Open grant
  • 2024 - 2029
    Pseudomyxoma Perionei Research Program
    PA Research Foundation
    Open grant

Supervision

Availability

Dr Cui Tu is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Dr Cui Tu's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au